BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...
One of the few bright spots in Boston’s life-science lab space market this year has dimmed.
DNA Price Action: Ginkgo Bioworks shares were up 16.7% at $7.26 at the time of publication, according to Benzinga Pro.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
In a recent transaction, Steven P. Coen, the Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), sold shares of the company's stock, reportedly to cover tax ...
Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...
Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...
TD Cowen analyst Brendan Smith maintained a Buy rating on Ginkgo Bioworks Holdings (DNA – Research Report) today and set a price target of $10.00. Brendan Smith’s rating is based on several strategic ...
Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...